Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Tisagenlecleucel B-cell childhood acute lymphoblastic leukemia not applicable detail...
JAK2 R938Q Ruxolitinib B-cell childhood acute lymphoblastic leukemia resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02228096 Phase II Tisagenlecleucel Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Completed
NCT02435849 Phase II Tisagenlecleucel Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA) Active, not recruiting
NCT02808442 Phase I UCART19 Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL) Recruiting
NCT02877303 Phase II Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Blinatumomab + Mercaptopurine + Methotrexate + Prednisone + Vincristine Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Vincristine Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ofatumumab + Vincristine Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Vincristine Blinatumomab and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia Recruiting
NCT02981628 Phase II inotuzumab ozogamicin Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Suspended
NCT03123939 Phase II Tisagenlecleucel Expanded Treatment Protocol in Acute Lymphoblastic Leukemia Active, not recruiting
NCT03595917 Phase I Asciminib + Dasatinib + Prednisone ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML Recruiting
NCT03605589 Phase I Blinatumomab + Pembrolizumab Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Recruiting
NCT03642626 Phase II Cyclophosphamide + Fludarabine + Tisagenlecleucel Cyclophosphamide + Fludarabine + KTE-C19 MT2017-45: CAR-T Cell Therapy for Heme Malignancies Recruiting
NCT03876769 Phase II Tisagenlecleucel Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA) Recruiting
NCT03913559 Phase II inotuzumab ozogamicin Cytarabine + Hydrocortisone + Methotrexate Acetaminophen + Diphenhydramine + Methylprednisolone Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia Recruiting
NCT03959085 Phase III Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Leucovorin + Mercaptopurine + Methotrexate + Vincristine inotuzumab ozogamicin Cytarabine + Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Cytarabine + Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine Cyclophosphamide + Cytarabine + Methotrexate + Pegaspargase + Thioguanine + Vincristine inotuzumab ozogamicin + Methotrexate Methotrexate + Pegaspargase + Vincristine Mercaptopurine + Methotrexate + Prednisolone + Vincristine Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Recruiting